Clinical trials: Breast Cancer, Breast Neoplasms
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Breast Cancer, Cervical Cancer
Community Clinic Model to Improve Early Detection of Breast and Cervical Cancers in Kenya
Kenya has a high incidence of breast and cervical cancers, and most women are diagnosed with late-stage disease. The investigators will conduct a study to assess the effectiveness and cost-effectiveness of strategies to increase…
- Trial name
- C3Link (NCT06572774)
- Testing
- C3Link Strategies
- Where
- Kenya
- Volunteers
- 5,400 people, healthy volunteers welcome
- Sponsor
- Implenomics
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
The Application of "HUAXI Hole 1" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast Reconstruction
This study is a multicenter, open-label, randomized controlled trial. It will prospectively compare outcomes between patients undergoing reverse-sequence endoscopic NSM (R-E-NSM) with direct-to-implant breast reconstruction…
- Trial name
- HUAXI-h-01 (NCT06995118)
- Testing
- HUAXI hole 1
- Where
- 20 sites in China
- Volunteers
- 337 people
- Sponsor
- Du Zhenggui
Vulvovaginal Atrophy, Breast Cancer
GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy.
In this prospective active-controlled randomized trial the investigators will assess for the first time ever the different local treatments of vulvovaginal atrophy in breast cancer patients on endocrine therapy.
- Trial name
- GRACE (NCT05562518)
- Testing
- Estrogen, dehydroepiandrosterone, Estrogen + probiotics
- Where
- Belgium
- Volunteers
- 31 people
- Sponsor
- University Hospital, Ghent
Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma
Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus neuroendocrine tumors or any other…
- Conditions
- Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma, Thymus Carcinoid
- Trial name
- PUTNET (NCT04276597)
- Testing
- 177Lu-DOTATOC
- Where
- United States
- Sponsor
- Excel Diagnostics and Nuclear Oncology Center
Breast Cancer, Neurocognitive Impairment
Examining a Common Complaint of Women Who Receive Chemotherapy for Breast Cancer- Cognitive Difficulty
This longitudinal project will investigate a common complaint of women who receive chemotherapy for breast cancer- cognitive difficulty.
- Conditions
- Breast Cancer, Neurocognitive Impairment, Quality of Life
- Trial name
- NCT01553097
- Testing
- Neurocognitive impairment observation
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Ovarian Cancer, Breast Cancer
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
Background: All cells go through cycles which allow them to divide. In normal cells, checkpoint kinase 1 (Chk1) and checkpoint kinase 2 (Chk2) (CHEK 2 (Chk1/2) stop cell division at various points to allow any damage to…
- Conditions
- Ovarian Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT02203513
- Testing
- LY2606368
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer Female, Joint Pain
Evaluation of the Efficacy of a Homeopathic Protocol in Patients With Non-metastatic Breast Cancer
Interventional, randomised, prospective, monocentric study
- Trial name
- ARHOMA2 (NCT04408560)
- Testing
- Rhus toxicodendron 9 CH + Ruta graveolens 5 CH (Homeopathic Granules), paracetamol (drug analgesic class1)
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Institut Jean-Godinot
HER2-positive Breast Cancer
SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer
This is a prospective, open-label, phase II, multicenter exploratory clinical study. Eligible female patients aged 18-75 years with stage II-III HER2-positive breast cancer will receive 4 cycles of SHR-A1811 (4.8 mg/kg…
- Trial name
- NCT07787338
- Testing
- SHR-A1811, THPy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Neoplasm
Total Body Irradiation for Bone Marrow Transplants: Collaborative Efforts
Most bone marrow transplantations for malignant and non-malignant disease include whole body irradiation. Techniques for administering that treatment, including patient positioning, lung and soft tissue compensation, dose rate…
- Trial name
- NCT00026858
- Testing
- collaboration
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Lactation Induced
Effect of OMEGA 3 Fatty Acids on Lactation Period
The World Health Organization (WHO) and the United Nations Children's Fund (UNICEF) recommend that babies be exclusively breastfed for the first 6 months from birth.
- Trial name
- NCT06111378
- Testing
- fish oil, linseed oil, walnut oil
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Manisa Celal Bayar University
Non Small Cell Lung Cancer, Breast Cancer
Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
This study is to examine which dose of YPEG-rhG-CSF, once-per-cycle, has similar efficacy and safety, comparing to PEG-rhG-CSF, once-per-cycle, in chemotherapy-induced neutropenia
- Trial name
- NCT02005458
- Testing
- YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle, YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle, YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
- Where
- 12 sites in China
- Volunteers
- 80 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Advanced Breast Cancer
Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer
This is a Open-label study of chidamide in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor positive, Her2 negative, advanced breast cancer who have received no or only one line of…
- Trial name
- NCT05047848
- Testing
- Chidamide, Fulvestrant
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Breast Neoplasm Female, Surgery
Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
Current guidelines lack definitive evidences about the relative benefits of locoregional surgery for the primary tumor in de novo stage IV breast cancer.
- Conditions
- Breast Neoplasm Female, Surgery, Advanced Breast Cancer
- Trial name
- SYSBTC-001 (NCT04456855)
- Testing
- Locoregional surgery
- Where
- 3 sites in China
- Volunteers
- 358 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer Female, Alopecia
Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy
Chemotherapy (CT) is a frequent and well established treatment in women with breast and gynecological tumors. Alopecia is one of the most common side effects of CT seriously impairing patient quality of life and body image.
- Trial name
- NCT04117815
- Testing
- Paxman Scalp Cooling System, Alopecia Assessments
- Where
- Austria
- Volunteers
- 128 people
- Sponsor
- Medical University Innsbruck
Breast Cancer, Osteoporosis
Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
RATIONALE: Zoledronate may reduce bone loss in patients receiving letrozole for breast cancer. PURPOSE: This clinical trial is studying how well zoledronate works in treating osteopenia or osteoporosis in postmenopausal women…
- Trial name
- NCT00436917
- Testing
- zoledronic acid, Letrozole as adjuvant therapy
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Head and Neck Neoplasms, Lung Neoplasms
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)
Background: Two experimental drugs, FdCyd (also called 5-fluoro-2'-deoxcytidine), and THU (also called tetrahydrouridine), are undergoing trials to test their effectiveness in treating cancer that has not responded to standard…
- Conditions
- Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
- Trial name
- NCT00978250
- Testing
- 5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)
- Where
- 4 sites in United States
- Volunteers
- 95 people
- Sponsor
- National Cancer Institute (NCI)
Triple Negative Breast Cancer
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
Eligible patients with stage 2 and 3 triple negative breast cancer will be treated with 4 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab. A PET scan will be performed at baseline and after 1 cycle of therapy.
- Trial name
- NeoADAPT (NCT06245889)
- Testing
- Paclitaxel, Carboplatin, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, Pain
Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer
RATIONALE: An outpatient educational and behavioral skills training program may help patients with metastatic breast or prostate cancer live longer and more comfortably.
- Conditions
- Breast Cancer, Pain, Prostate Cancer
- Trial name
- NCT00002668
- Testing
- Observation, Educational Intervention and Behavioral Skills Training
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 13 people
- Sponsor
- Eastern Cooperative Oncology Group
Breast Neoplasm, Breast Cancer
Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors
Fear of cancer recurrence (FCR) is a highly prevalent, disruptive, and under-treated problem for breast cancer survivors. This randomized controlled trial will test the efficacy of group-based Acceptance and Commitment Therapy…
- Conditions
- Breast Neoplasm, Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast
- Trial name
- NCT05364450
- Testing
- Enhanced Usual Care, Acceptance Commitment Therapy, Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 390 people
- Sponsor
- Indiana University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.